Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rotigotine
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BioNxt Reports Update on Commercialization of Rotigotine Patch for Treatment of Parkinson's Disease
Details : Rotigotine transdermal patch is used to treat Parkinson disease. It is a dopamine agonist that works on the nervous system to help treat the symptoms of Parkinson disease. Rotigotine is also used to treat a condition called Restless Legs Syndrome (RLS).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 13, 2023
Lead Product(s) : Rotigotine
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?